Impact of Prophylactic Bone Radiation Therapy in Patients With Bone Metastases.

Starting soon · Phase 3

Conditions studied: Bone Metastases

In brief

Radiation therapy is a common treatment for painful bone metastases, proving effective in 1 to 2/3 of cases after 1 to 10 sessions, with stereotactic body radiation therapy (SBRT) likely offering superior results. Radiation therapy is also used to prevent bone events, although its use is not standardized; the decision to administer it is made by clinicians or through multidisciplinary team (MDT) discussions. Recently, it has been shown that preventive radiation therapy can reduce the risk of skeletal-related events (SREs) in patients at high risk for bone events. The objective is to compare active surveillance with preventive radiation therapy in patients at intermediate risk for bone events.

Key facts

Study ID

NCT07733193

Run by

Centre Henri Becquerel

People needed

154

Starts

2026-09-01

Expected to finish

2030-11-01

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women, 18 years of age or older
• Patients with solid cancer and bone metastases
• Patients with bone lesions considered to be at intermediate risk for skeletal-related events (SINS score between 7 and 12, Mirels 8) or patients with lesions accompanied by Grade 1 epiduritis (Bilsky)
• Enrolled in or covered by a social insurance program
• Patients with an estimated life expectancy of more than 6 months

You may not qualify if…

• Hematologic disease
• Patients with a lesion at high risk for skeletal-related events (SINS score of 13 or higher, MIRELS score of 9 or higher, or a multidisciplinary team (MDT) recommendation that surgery is necessary)
• Patients with pain secondary to bone lesions requiring radiation therapy
• Contraindication to radiation therapy due to a history of radiation therapy at the same site or a condition contraindicating radiation therapy
• Pregnant or breastfeeding women
• Contraindication to MRI in cases of spinal lesions; contrast-enhanced CT scan
• Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, geographic issues, etc.)
• Patients under legal guardianship or conservatorship
• Patients classified as WHO 3 or 4

Where it is running

• Institut de Cancérologie de Lorraine — Nancy, France
• Centre Henri Becquerel — Rouen, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.